Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children-Reference-Cited by-同舟云学术

Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children

Published:2018-11-05 Issue:1 Volume:85 Page:100-113
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Johnson Trevor N.¹,Cleary Yumi²,Parrott Neil²,Reigner Bruno²,Smith James R.²,Toovey Stephen³^ORCID

Affiliation:

1. Certara UK Limited (Simcyp) Level 2‐Acero 1 Concourse Way Sheffield UK

2. Pharma Research & Early DevelopmentRoche Innovation Center Basel, F. Hoffmann‐La Roche Ltd Basel Switzerland

3. Pegasus Research Basel Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13764

Reference41 articles.

1. WHO.World Malaria Report. In Geneva: World Health Organisation 2016.

2. Rolling back malaria: how well is Europe doing?

3. The position of mefloquine as a 21st century malaria chemoprophylaxis

4. Imported Malaria in Children in Industrialized Countries, 1992–2002

5. Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Dose-Proportionality, and Tolerability of Intravenous Tanespimycin (17-AAG) in Single and Multiple Doses in Dogs: A Potential Novel Treatment for Canine Visceral Leishmaniasis;Pharmaceuticals;2024-06-11

2. Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants;British Journal of Clinical Pharmacology;2024-06-10

3. Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach;Frontiers in Pharmacology;2024-03-04

4. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment;Scientific Reports;2023-09-25

5. Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights;British Journal of Clinical Pharmacology;2023-07-02